aurothioglucose ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4349 12192-57-3

Description:

MoleculeDescription

Synonyms:

  • aurothioglucose
  • aureotan
  • gold thioglucose
  • thioglucosoaurate
A thioglucose derivative used as an antirheumatic and experimentally to produce obesity in animals.
  • Molecular weight: 392.18
  • Formula: C6H11AuO5S
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
2.40 mg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.25 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1927 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01CB04 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
SPECIFIC ANTIRHEUMATIC AGENTS
Gold preparations
MeSH PA D018501 Antirheumatic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Rheumatoid arthritis indication 69896004 DOID:7148
Juvenile rheumatoid arthritis indication 410795001
Psoriasis with arthropathy off-label use 33339001
Felty's syndrome off-label use 57160007 DOID:11042
Necrotizing enterocolitis in fetus OR newborn contraindication 2707005
Hypertensive disorder contraindication 38341003 DOID:10763
Eczema contraindication 43116000
Chronic heart failure contraindication 48447003
Fibrosis of lung contraindication 51615001 DOID:3770
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Colitis contraindication 64226004 DOID:0060180
Diabetes mellitus contraindication 73211009 DOID:9351
Sjรถgren's syndrome contraindication 83901003 DOID:12894
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Urticaria contraindication 126485001
Inflammatory disease of liver contraindication 128241005
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Disease of liver contraindication 235856003 DOID:409
Eruption of skin contraindication 271807003 DOID:0050486
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Ultraviolet light therapy contraindication 363695005
Erythroderma contraindication 399992009
Severe Debilitation contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Thioredoxin reductase 1, cytoplasmic Enzyme Ki 8.40 WOMBAT-PK
5-hydroxytryptamine receptor 3A Ion channel Ki 10.50 CHEMBL
5-hydroxytryptamine receptor 3B Ion channel Kd 9.85 CHEMBL
Sulfide:quinone oxidoreductase, mitochondrial Unclassified IC50 6.03 CHEMBL

External reference:

IDSource
4018804 VUID
N0000147107 NUI
D00991 KEGG_DRUG
4018804 VANDF
C0018033 UMLSCUI
CHEBI:2930 CHEBI
CHEMBL2354773 ChEMBL_ID
CHEMBL1189679 ChEMBL_ID
CHEMBL1697725 ChEMBL_ID
D006051 MESH_DESCRIPTOR_UI
DB09121 DRUGBANK_ID
2P2V9Q0E78 UNII
3032577 PUBCHEM_CID
4980 RXNORM
4232 MMSL
d00820 MMSL
002395 NDDF
21880003 SNOMEDCT_US
768512005 SNOMEDCT_US

Pharmaceutical products:

None